Brain implants, or brain-computer interfaces (BCIs), are becoming a new focal point in the U.S.-China rivalry, offering hope for neurological conditions. Billionaires are investing heavily in this field, yet a national security analysis suggests China is outpacing U.S. development in manufacturing, data, and commercialization. This shift could impact not only healthcare but also U.S. military capabilities and AI training. China has already achieved a significant milestone with the first commercial approval of a BCI for spinal cord injuries, designating it a "future industry." The U.S. faces regulatory bottlenecks and funding concerns, hindering its progress in bringing BCIs to market. The analysis recommends a clearer FDA pathway and CMS payment structure for these devices. Senator Todd Young emphasizes the need for a coordinated U.S. biotechnology strategy to foster innovation and commercialization. BCIs also raise complex ethical and privacy issues regarding data control and the applicability of existing laws. China currently lacks specific neural-data privacy regulations. Despite ongoing challenges with device longevity and patient recruitment for trials, BCIs hold potential for both medical and non-medical applications, such as controlling drones. The U.S. is considering including brain implants in programs to expedite Medicare coverage for breakthrough devices.